$LPNT (LifePoint Health, Inc.)

$LPNT {{ '2016-02-03T12:19:16+0000' | timeago}} • Announcement

Healthcare services provider $LPNT said that it has wrapped up its acquisition of Providence Hospitals from Sisters of Charity System, which originally founded Providence. Providence includes two hospitals, 13 physician practices and a network of rehabilitation centers. The hospital employs more than 2,000 staff.

$KND {{ '2017-09-20T20:58:31+0000' | timeago}} • Announcement

$KND expects a one-time pretax earnings impact from Hurricanes Irma and Harvey of approx. $20MM in aggregate for 3Q17. The company does not expect any significant impact on its financial results in 4Q17 or beyond. In total, the businesses in the storm-affected areas represent approx. 16% of aggregated consolidated revenues.

$EVHC {{ '2017-09-19T12:30:35+0000' | timeago}} • Announcement

As part of $EVHC's organizational changes, Karey Witty, a veteran healthcare executive, has been appointed to the new role of EVP and COO, effective Oct 2, 2017. Kevin Eastridge, currently CAO, will succeed Claire Gulmi as CFO, effective same day.

$EVHC {{ '2017-09-19T12:24:50+0000' | timeago}} • Announcement

$EVHC announced the authorization of a program to repurchase up to $250MM of its common stock, which represents approx 4% of its current market capitalization.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$ENSG {{ '2017-09-12T13:49:58+0000' | timeago}} • Announcement

$ENSG has declared a quarterly cash dividend of $0.0425 per share of its common stock, payable on or before Oct 31, 2017, to shareholders as on Sept 30, 2017.

$BMY {{ '2017-09-11T10:59:32+0000' | timeago}} • Announcement

$BMY said Opdivo plus Yervoy combination demonstrated superior overall survival and showed durable responses in patients with previously untreated advanced or metastatic renal cell carcinoma in phase 3 CheckMate -214 trial. The combination lowered the risk of death by 37% and improved overall survival in all randomized patients.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$ABBV {{ '2017-09-08T16:14:15+0000' | timeago}} • Announcement

$ABBV's BoD declared a quarterly cash dividend of $0.64 per share. The dividend is payable on Nov. 15, 2017 to stockholders of record on Oct. 13, 2017. Since the company's inception in 2013, $ABBV has increased its dividend by 60%.

$INCY {{ '2017-09-08T12:59:10+0000' | timeago}} • Announcement

$INCY priced its underwritten public offering of 4.945MM shares of its common stock. The company has granted the underwriter an option to purchase up to an additional 741,750 shares of common stock. The offering is expected to close on Sept. 12, 2017.

$AMGN {{ '2017-09-07T20:44:44+0000' | timeago}} • Announcement

$AMGN's new data demonstrates Aimovig reducing monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet meed. Aimovig is the only investigational biologic product specifically designed to prevent migraine by blocking the CGRP receptor, which is associated with migraine activation.

$BMY {{ '2017-09-07T13:34:21+0000' | timeago}} • Announcement

$BMY said a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) met its co-primary endpoint. This demonstrates superior overall survival (OS) compared to sunitinib in intermediate- and poor-risk patients.

$AMGN {{ '2017-09-07T12:11:23+0000' | timeago}} • Announcement

$AMGN announced results from the PATHWAY Phase 2b trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. Tezepelumab is a novel anti-thymic stromal lymphopoietin monoclonal antibody being developed by $AZN in collaboration with $AMGN.

$ABBV {{ '2017-09-06T15:45:07+0000' | timeago}} • Announcement

$ABBV, in cooperation with $NBIX, has submitted a New Drug Application to the FDA for elagolix, an investigational, orally administered gonadotropin-releasing hormone antagonist, being evaluated for the management of endometriosis with associated pain. The pain includes daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse.

$ENSG {{ '2017-09-05T13:11:13+0000' | timeago}} • Announcement

$ENSG acquired the real estate and operations of two skilled nursing facilities in Arizona. The company expects the facilities to be accretive to earnings in 2018. This brings $ENSG growing portfolio to 229 facilities, 63 of which are owned, 21 hospice agencies, 18 home health agencies and 3 home care businesses across 14 states.

$ENSG {{ '2017-09-05T13:07:25+0000' | timeago}} • Announcement

$ENSG acquired the real estate and operations of two skilled nursing facilities in Arizona, effective Sept. 1, 2017. This includes: Desert Blossom Health and Rehabilitation Center, an 88-bed skilled nursing facility located in Mesa, Arizona; and Pueblo Springs Rehabilitation Center, an 115-bed skilled nursing facility located in Tucson, Arizona.

$HLS {{ '2017-08-31T22:27:53+0000' | timeago}} • Announcement

$HLS announced the formation of the Post-Acute Innovation Center in collaboration with $CERN to develop enhanced tools to manage patients across the continuum of care. The Post-Acute Innovation Center will develop clinical decision support tools designed to more effectively and efficiently manage patients across multiple care settings.

Recent Transcripts

THC (Tenet Healthcare Corp.)
Tuesday, August 8 2017 - 2:00pm
EVHC (Envision Healthcare Holdings, Inc.)
Tuesday, August 8 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
ENSG (The Ensign Group, Inc.)
Friday, August 4 2017 - 5:00pm
KND (Kindred Healthcare Inc.)
Friday, August 4 2017 - 1:00pm
SEM (Select Medical Holdings Corporation)
Friday, August 4 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
CYH (Community Health Systems, Inc.)
Wednesday, August 2 2017 - 3:00pm
FVE (Five Star Quality Care Inc.)
Wednesday, August 2 2017 - 2:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
LPNT (LifePoint Health, Inc.)
Tuesday, August 1 2017 - 2:00pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Tuesday, August 1 2017 - 1:30pm
HLS (HEALTHSOUTH Corp.)
Tuesday, August 1 2017 - 1:00pm
MD (MEDNAX, Inc.)
Friday, July 28 2017 - 2:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
MGLN (Magellan Health, Inc.)
Friday, July 28 2017 - 12:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm

AlphaGraphics you may like